Netarsudil Ophthalmic

DRUG5 trials

Sponsors

University of the Incarnate Word, Aerie Pharmaceuticals, Massachusetts Eye and Ear Infirmary, Salus University

Conditions

Corneal EdemaFuchs' Endothelial DystrophyGlaucoma, Open-AngleNormal Tension GlaucomaProliferative VitreoretinopathyRhegmatogenous Retinal Detachment

Early Phase 1

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

University of the Incarnate WordGlaucoma, Open-Angle

Start: 2020-01-06End: 2021-01-31Target: 10Updated: 2020-04-14

Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty

CompletedNCT04752020

Massachusetts Eye and Ear InfirmaryFuchs' Endothelial Dystrophy

Start: 2021-03-28End: 2023-12-30Updated: 2024-03-13

Phase 1

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

RecruitingNCT06033703

Massachusetts Eye and Ear InfirmaryProliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment

Start: 2025-01-14End: 2026-12-31Target: 48Updated: 2025-10-28

Phase 2

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy

CompletedNCT04498169

Aerie PharmaceuticalsCorneal Edema

Start: 2020-09-17End: 2021-08-11Updated: 2022-09-15

Phase 4

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

Salus UniversityNormal Tension Glaucoma

Start: 2021-08-31End: 2022-08-31Target: 115Updated: 2021-08-06

Related Papers

Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy

Journal of Ocular Pharmacology and Therapeutics2022-11-0316 citations